menu One Stop Shop For Reports One Stop Shop For Reports
search more_vert
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Medical Devices & Supplies
      • Pharmaceuticals
  • Report Library
  • Who Trust Us
  • Datafeature
  • [email protected]
  • +1 718 618 4351 (International)
  • +91 78878 22626 (Asia)

More Results

menu One Stop Shop For Reports One Stop Shop For Reports
search more_vert
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Medical Devices & Supplies
      • Pharmaceuticals
  • Report Library
  • Who Trust Us
  • Datafeature
Home ➤ Companies ➤ Amphastar Pharmaceuticals Inc Company Profile

Amphastar Pharmaceuticals Inc Company Profile

Amphastar-Pharmaceuticals Inc-logo

Amphastar Pharmaceuticals Inc.

Pharmaceuticals

  • Type

    Public

  • Headquarters

    The US

  • Establishment

    1996

  • Key Management

    Mr. Jack Y. Zhang (CEO)

  • Revenue

    ~437.8(2021)

  • Headcount

    ~245(2021)

  • Website

    www.amphastar.com

Business Description

Amphastar Pharmaceuticals Inc. develops, markets, and sells technically difficult and proprietary injectable, intramuscular, and intranasal product lines. The company is divided into Finished Pharmaceutical Products (API) and Active Pharmaceutical Ingredients Products (API). The Finished Pharmaceutical Products segment produces, markets, distributes, and markets Primatene Mist and other critical care drugs. Active Pharmaceutical Ingredients Products manufactures and distributes porcine and human insulin. The company was founded on February 29, 1996, by Zi-Ping Luo, and Yong Feng Zhang, and has its headquarters in Rancho Cucamonga (CA).

Key Financials

Revenue (US$ Mn):

 

  • Amphastar Pharmaceuticals Inc’s annual revenue for 2021 was US$ 438 Mn, a 25.16% increase from 2020
  • The annual revenue generated by Amphastar Pharmaceuticals Inc in 2020 was US$ 350 Mn

 

Operating Income (US$ Mn):

 

  • US$ 14 Mn was Amphastar Pharmaceuticals Inc’s operating income in 2021, a 125.4% increase from 2020 figures
  • Amphastar Pharmaceuticals Inc indexed a -89.53% decrease in operating incomes from 2019, amounting to US$ 6 Mn in 2020
  • Amphastar Pharmaceuticals Inc generated an operating income of US$ 60 Mn in 2019

 

Net Income (US$ Mn):

 

  • US$ 63 Mn was the net income generated by Amphastar Pharmaceuticals Inc in 2021
  • Amphastar Pharmaceuticals Inc’s net income for 2020 was US$ 1 Mn, a -97.83% decrease from 2019

 

Operating Margin %:

 

  • Amphastar Pharmaceuticals Inc’s operating margin for 2021 was 3%, a 77.78% increase from 2020
  • The operating margin generated by Amphastar Pharmaceuticals Inc in 2020 was 2%

 

Gross Margin %:

 

  • 14% was Amphastar Pharmaceuticals Inc’s gross margin in 2021, a 7050% increase from 2020 figures
  • Amphastar Pharmaceuticals Inc indexed a -98.59% decrease in gross margins from 2019, amounting to % in 2020
  • Amphastar Pharmaceuticals Inc generated a gross margin of 14% in 2019

 

SWOT Analysis

Strengths

 

Get this premium content

The Premium data is Locked
Buy Now to Unlock Premium Data

Table of Content

  1. Business Description
  2. Key Financials
  3. SWOT Analysis
    1. Strength
    2. Weakness
    3. Opportunities
    4. Threats
    5. Key Developments
      1. Year 2022
      2. Year 2021
      3. Year 2020
      4. Year 2019
  • US $299
  • US $499
Buy Now
✖

Request For Company Data

We'll get back to you as quickly as possible

Primary Sidebar

  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 618 4351 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
  • Report Library
Secured Payment Options
Secured Payment Options

© 2023 Market.Us. All Rights Reserved.